Jennifer Lachey - 24 Jun 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
24 Jun 2021
Net transactions value
+$1,950
Form type
4
Filing time
25 Jun 2021, 18:29:35 UTC
Previous filing
15 Jun 2021
Next filing
18 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $1,950 +6,500 +8.3% $0.3000* 84,407 24 Jun 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -6,500 -83% $0.000000 1,293 24 Jun 2021 Common Stock 6,500 $0.3000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.